摘要
目的分析玻璃体腔注射康柏西普治疗视网膜静脉阻塞(RVO)继发黄斑水肿的临床有效性和安全性。方法回顾性研究。临床检查确诊的RVO继发黄斑水肿患者24例(24只眼),初始3个月,每个月给予玻璃体腔内注射康柏西普0.5 mg,以后根据患者病情需要决定是否重复注射治疗。随访6个月,常规眼科检查、眼底照相、相干光断层扫描等,记录最佳矫正视力(BCVA)、中央视网膜厚度(CRT)的变化以及不良反应,与治疗前进行比较分析。结果治疗后1、2、3、6个月,各时间点BCVA均较治疗前提高,差异有统计学意义(P=0.000)。治疗后1、2、3、6个月,各时间点CRT与治疗前相比均有下降,差异有统计学意义(P=0.000)。治疗后6个月,BCVA与治疗前基线BCVA呈正相关,差异有统计学意义(r=0.808,P=0.000)。治疗后6个月BCVA与治疗前CRT(r=0.334,P=0.111)、治疗后6个月CRT(r=0.295,P=0.162)无明显相关性,差异无统计学意义(P>0.05)。结论玻璃体腔注射康柏西普治疗RVO继发黄斑水肿在短期内是安全有效的,视力预后与治疗前基线视力呈正相关。
Objective To evaluate effectiveness and safety of intravitreal injections of Conbercept for macular edema secondary to retinal vein occlusion. Methods It is retrospective case study. The patients were confirmed by clinical examination of macular edema secondary to retinal vein occlusion. 24 cases were enrolled in this study. All the patients were treated with 0. 5 mg Conbercept in the first three months. The BCVA,fundus manifestations,OCT and complications were observed every month. Results During the 1,2,3,6 months after treatment,the mean BCVA were all improved with statistically significant difference（ P = 0. 000）. During the 1,2,3,6 months after treatment,the mean CRT were all decreased with statistically significant difference（ P = 0. 000）. The BCVA of the 6 th month were related with the BCVA at baseline（ r = 0. 808,P = 0. 000）. The BCVA of the 6 th month were not related with CRT at baseline（ r = 0. 334,P = 0. 111） or the 6 th month（ r = 0. 295,P = 0. 162）. Conclusions Conbercept is safe and effective to treat macular edema secondary to retinal vein occlusion. And the BCVA after treatment were related with the BCVA at baseline.
出处
《临床眼科杂志》
2017年第6期494-497,共4页
Journal of Clinical Ophthalmology
